Tecemotide: An antigen-specific cancer immunotherapy

Gregory T. Wurz, Chiao Jung Kao, Michael Wolf, Michael W. DeGregorio

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


The identification of tumor-associated antigens (TAA) has made possible the development of antigen-specific cancer immunotherapies such as tecemotide. One of those is mucin 1 (MUC1), a cell membrane glycoprotein expressed on some epithelial tissues such as breast and lung. In cancer, MUC1 becomes overexpressed and aberrantly glycosylated, exposing the immunogenic tandem repeat units in the extracellular domain of MUC1. Designed to target tumor associated MUC1, tecemotide is being evaluated in Phase III clinical trials for treatment of unresectable stage IIIA/IIIB non-small cell lung cancer (NSCLC) as maintenance therapy following chemoradiotherapy. Additional Phase II studies in other indications are ongoing. This review discusses the preclinical and clinical development of tecemotide, ongoing preclinical studies of tecemotide in human MUC1 transgenic mouse models of breast and lung cancer, and the potential application of these models for optimizing the timing of chemoradiotherapy and tecemotide immunotherapy to achieve the best treatment outcome for patients.

Original languageEnglish (US)
Pages (from-to)3383-3393
Number of pages11
JournalHuman Vaccines and Immunotherapeutics
Issue number11
StatePublished - Nov 1 2014


  • Chemoradiotherapy
  • Immunotherapy
  • MUC1
  • Non-small cell lung cancer
  • Tecemotide

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology


Dive into the research topics of 'Tecemotide: An antigen-specific cancer immunotherapy'. Together they form a unique fingerprint.

Cite this